Y-mAbs Therapeutics (YMAB) Lifted to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Y-mAbs Therapeutics (NASDAQ:YMAB) from a sell rating to a hold rating in a report issued on Saturday, Zacks.com reports.

According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

Separately, HC Wainwright started coverage on Y-mAbs Therapeutics in a research note on Monday, April 1st. They issued a buy rating and a $36.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of Buy and an average price target of $30.00.

Y-mAbs Therapeutics stock traded down $0.05 during midday trading on Friday, reaching $23.48. The company’s stock had a trading volume of 84,007 shares, compared to its average volume of 117,609. Y-mAbs Therapeutics has a fifty-two week low of $15.17 and a fifty-two week high of $31.00. The stock has a market cap of $802.88 million and a PE ratio of -15.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.11). As a group, analysts anticipate that Y-mAbs Therapeutics will post -1.67 earnings per share for the current year.

In other news, insider Thomas Gad sold 250,000 shares of Y-mAbs Therapeutics stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $25.89, for a total transaction of $6,472,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Several institutional investors and hedge funds have recently bought and sold shares of YMAB. Citigroup Inc. acquired a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth about $37,000. Strs Ohio acquired a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth about $38,000. BNP Paribas Arbitrage SA acquired a new stake in shares of Y-mAbs Therapeutics during the first quarter worth about $38,000. American International Group Inc. acquired a new stake in shares of Y-mAbs Therapeutics during the fourth quarter worth about $93,000. Finally, Bank of America Corp DE increased its position in shares of Y-mAbs Therapeutics by 3,056.5% during the fourth quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after purchasing an additional 5,838 shares in the last quarter. Institutional investors and hedge funds own 25.41% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Article: Stop Order

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.